HDAC inhibitors for the treatment of diabetic peripheral neuropathy
The invention relates to HDAC inhibitors for use in the treatment of diabetic peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating diabetic peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor.
1. A method for treating diabetic peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC6-specific inhibitor.
2. The method of claim 1 , wherein the HDAC6-specific inhibitor is a compound of Formula II:
or a pharmaceutically acceptable salt thereof,
wherein ring B is aryl or heteroaryl optionally substituted by OH, halo, or C 1-6 -alkyl;
R 1 is aryl or heteroaryl optionally substituted by OH, halo, or C 1-6 -alkyl; and
R is H or C 1-6 -alkyl.
3. The method of claim 2 , wherein the compound of Formula II is:
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the HDAC6-specific inhibitor is administered by oral administration.